临床药师团队

研究生带教团队

团队形成了稳定的高素质临床药师人才梯队，建立了规范的住院药师带教培训模式，现有临床药师分布在心内、心外、心血管危重症抢救、抗感染、内分泌等专业，参与每日查房，审核患者医嘱，参与患者入院时治疗药物重整及初始治疗方案制定、住院期间药物治疗监测及方案的调整、出院时患者的用药指导等工作。作为国家临床药师培训基地，承接全国临床药师的培训任务。同时我院已开展MTM门诊，具有多名已获得资格的MTM临床药师，为患者提供高质量的药物治疗管理服务。

团队已培养博士、硕士研究生20余人次，已毕业学生均从事临床药学专业工作。

1. 北京市卫健委，北京市研究型病房建设项目，2021.01-2024.12

2. 科技部十三五 “新药创制”重大专项，2017ZX090304017，心血管疾病药物临床研究示范性平台，2017-06至2020-12

3. 北京市医管局, 重点医学专业发展计划, ZYLX201805, 心血管临床药学, 2018-09 至 2020-12

4. 国家重点研发计划，“精准医学研究”重点专项，冠心病和心房颤动的诊疗规范和应用方案的精准化研究，2017YFC0908800，2017-03至2019-12

5. 国家自然科学基金，81541169，基于“多维度体内过程与生物效应”的丹参饮归经及活血化瘀机制研究，2016-01至2016-12

6. 北京市自然科学基金，2153040，基于代谢组学的高胆固醇血症冠心病患者血浆氧化应激生物标记物探索性研究，2015-01至2016-06

重要学术论文：

1: Clinical Outcomes of Individualized Antiplatelet Therapy Based on Platelet Function Test in Patients After Percutaneous Coronary Intervention: A Systematic Review and Meta-analysis. J Cardiovasc Pharmacol. 2023 Apr 1;81(4):270-279. Peng W, Zhang Y, Lin B, Lin Y* SCI (IF=3.00)

2: Efficacy and Safety of Prolonged Dual Antiplatelet Therapy after Percutaneous Coronary Intervention in Acute Coronary Syndrome Patients. Glob Heart. 2023 Mar 13;18(1):11. Han J, Zhang Y, Shi X, Lin B, Zhang Y, Zhang R, Wang Y, Yan J, Lin Y* SCI (IF=3.70)

3: Low-dose and standard-dose ticagrelor compared with clopidogrel in patients with acute coronary syndromes: A cohort study from china. Front Cardiovasc Med. 2022 Jul 26;9:937261. Peng W, Zhang Y, Lin Y* SCI (IF=3.60)

4: Ticagrelor vs. Clopidogrel in Older Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: Insights From a Real-World Registry. Front Cardiovasc Med. 2022,9:1-10. Zhang Y, Peng W, Shi X, Han J, Wang Y, Fang Z, Lin Y* SCI (IF=6.050)

5: Metformin and the risk of neurodegenerative diseases in patients with diabetes: A meta-analysis of population-based cohort studies. Diabet Med. 2022. Zhang Y, Zhang Y, Shi X, Han J, Lin B, Peng W, Mei Z*, Lin Y* SCI(IF=4.359)

6: Personalized Antiplatelet Therapy Based on CYP2C19 Genotypes in Chinese ACS Patients Undergoing PCI: A Randomized Controlled Trial. Front Cardiovasc Med. 2021,16（8）:1-9. Shi X#, Zhang Y#, Zhang Y#, Zhang R, Lin B, Han J, Li W, Fang Z, Yan J, Wang Y, Zheng Z, Lv Y, Lin Y* SCI(IF=6.050)

7: Clopidogrel versus Ticagrelor in CYP2C19 Loss-of-Function Allele Noncarriers: A Real-World Study in China. Thromb Haemost. 2021. Zhang Y, Zhang Y, Shi X, Lin B, Han J, Wang Y, Yan J, Peng W, Li W, Zheng Z, Lin Y* SCI (IF=5.24)

8: Convallatoxin Promotes M2 Macrophage Polarization to Attenuate Atherosclerosis Through PPARγ-Integrin α v β 5 Signaling Pathway. Drug Des Devel Ther. 2021,23;15:803-812. Zhang Y, Shi X, Han J, Peng W, Fang Z, Zhou Y, Xu X, Lin J, Xiao F, Zhao L, Lin Y*. SCI (IF=3.216)

9: Danthron attenuates experimental atherosclerosis by targeting foam cell formation. Exp Physiol. 2021,106(3):653-662. Shi X, Zhang Y, Lin B, Zhou Y, Suo W, Wei J, Zhang L, Lin J, Xiao F, Zhao L, Lin Y* SCI(IF=2.431)

10: Impact of Implementing CYP2C19 Genotype-Guided Antiplatelet Therapy on P2Y12 Inhibitor Selection and Clinical Outcomes in Acute Coronary Syndrome Patients After Percutaneous Coronary Intervention: A Real-World Study in China. Front Pharmacol. 2021,20;11:582929. Zhang Y, Shi XJ, Peng WX, Han JL, Lin BD, Zhang R, Zhang YN, Yan JL, Wei JJ, Wang YF, Chen SW, Nan N, Fang ZW, Zeng Y, Lin Y*. SCI(IF=4.225)

11: Distribution Analysis of Salvianolic Acids in Myocardial Ischemic Pig Tissues by Automated Liquid Extraction Surface Analysis Coupled with Tandem Mass Spectrometry. Evidence-Based Complementary and Alternative Medicine. Evidence-Based Complementary and Alternative Medicine. 2020,2020:1-9. Qi Qiu #*, Jinglin Cao#, Yu Mu#, Yang Lin#, Yunnan Zhang, Jing Li, Xiujin Shi SCI(IF=1.93)

12: Towards low cost, multiplex clinical genotyping: 4-fluorescent Kompetitive Allele-Specific PCR and its application on pharmacogenetics. Plos One. 2020,15(3):e0230445. Wei Suo#, Xiujin Shi, Xiao Li, Sha Xu, Yang Lin* SCI(IF=2.74)

13: Both CYP2C19 and PON1 Q192R Genotypes Influence Platelet Response to Clopidogrel by Thrombelastography in Patients with Acute Coronary Syndrome. Cardiovascular Therapeutics. 2019,3470145（1-8）:8页. Peng W#, Shi X, Xu X, Lin Y* SCI(IF=2.32)

14: Serum metabolomics reveals the progression of coronaryartery stenosis in patients with hypercholesterolemia: a pilot study. Blood Coagulation and Fibrinolysis.. 2019,30(5):205-216. Qi Qiu, Yong Wang, Shan Jing, Yanhua Chen, Jinglin Cao, Yu Pan,Ming Ye and Yang Lin* SCI(IF=1.09)

15: Time Course of the Effects of Buxin Yishen Decoction in Promoting Heart Function and Inhibiting the Progression of Renal Fibrosis in Myocardial Infarction Caused Type 2 Cardiorenal Syndrome Rats. Frontiers in Pharmacology. 2019,10:15pages. Qi Qiu*, Jinglin Cao, Yong Wang, Yunnan Zhang, Yun Wei, Xiaoyan Hao, Yu Mu and Yang Lin* SCI(IF=3.9)

主编或副主编的著作：

冠心病患者用药自我管理一本通，主编，北京科学技术出版社，2021年，ISBN: 978-7-5714-1207-4